You are here

Public notice of final decisions - ACMS#29, ACCS#27, Joint ACMS-ACCS#24, March 2020

Scheduling medicines and poisons

24 August 2020

Book pagination

3.1.1 Rizatriptan

3 Final decisions on proposed amendments to the current Poisons Standard under regulation 42ZCZR

Note

New text is shown as green, larger font, with a horizontal line above it.

3.1 Final decisions on proposed amendments referred to the Advisory Committee on Medicines Scheduling (ACMS #29, March 2020)

Final decision in relation to rizatriptan

Final decision

Pursuant to regulation 42ZCZR of the Regulations, a Delegate of the Secretary has made a final decision to confirm the interim decision and amend the current Poisons Standard in relation to rizatriptan as follows:

Schedule 4 - Amend Entry

RIZATRIPTAN except when included in Schedule 3.

Schedule 3 - New Entry

RIZATRIPTAN when in divided oral preparations containing 5 milligrams or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well-established pattern of migraine symptoms.

Appendix H - New Entry

RIZATRIPTAN

Index - Amend Entry

RIZATRIPTAN

Schedule 4
Schedule 3
Appendix H

Materials considered

In making this final decision, the Delegate considered the following material:

  • The application to amend the current Poisons Standard with respect to rizatriptan;
  • The five public submissions received in response to the pre-meeting consultation under regulation 42ZCZK of the Regulations;
  • The advice received from the Advisory Committee on Medicines Scheduling (ACMS #29);
  • The one public submission received in response to the interim decision consultation under regulation 42ZCZP of the Regulations;
  • Subsection 52E(1) of the Therapeutic Goods Act 1989, in particular (a) the risks and benefits of the use of a substance; (b) the purposes for which a substance is to be used and the extent of use of a substance; (c) the toxicity of a substance; (d) the dosage, formulation, labelling, packaging and presentation of a substance; and (e) the potential for abuse of a substance; and (f) any other matters considered necessary to protect public health;
  • The Australian Health Ministers' Advisory Council's Scheduling Policy Framework (SPF 2018); and
  • The Scheduling handbook: Guidance for amending the Poisons Standard.
Reasons for the final decision (including findings on material questions of fact)

I have made a final decision to confirm both my interim decision and the reasons published in my interim decision, to amend the current Poisons Standard to down-schedule rizatriptan from Schedule 4 to Schedule 3. My reasons for making the final decision are those set out in the interim decision. In making my final decision, I have taken into account the material detailed in the interim decision and the public submission received before the second closing date in response to the call for further submissions published on 10 June 2020 under regulation 42ZCZP of the Regulations. I note the public submission was in support of my interim decision.

Date of effect of the decision

1 February 2021

Book pagination